HLB Pharm's Cumulative 3-Quarter Revenue Jumps 34% on Balanced Growth

Achieved cumulative operating profit of 1.85 billion won on balanced growth across major business divisions

- Upgrading production systems centered on the new Hyangnam plant... Strengthening the foundation for mid-to-long-term growth

HLB Pharm announced that its cumulative consolidated revenue for the first three quarters of this year reached 190.4 billion won, a 34.0% increase compared to the same period last year. Cumulative operating profit surged 707.5% year-on-year to 1.85 billion won, achieving simultaneous top-line growth and profitability improvement.

Standalone revenue for the third quarter stood at 62.5 billion won, up 3.1% from the same period last year, with operating profit recording 850 million won.

By business segment, cumulative third-quarter sales of ethical drugs (ETC) rose 11.5% year-on-year to 104.6 billion won. Contract manufacturing organization (CMO) sales increased by 9.0% to 5.26 billion won, while consumer healthcare sales grew 40.3% to 16.4 billion won.

Pharmaceutical distribution subsidiary Shinhwa Advance also maintained its sales growth momentum following its incorporation into the group. Shinhwa Advance's cumulative third-quarter revenue increased by 18.0% to 65.987 billion won, compared to 55.916 billion won in the cumulative third quarter of last year.

HLB Pharm plans to continue expanding sales in major businesses such as ethical drugs and consumer healthcare while broadening its growth foundation by strengthening production and sales competitiveness.

Over the long term, the company plans to expand its annual drug production capacity to 700 million tablets through the construction of the new Hyangnam plant. Its strategy is to enhance manufacturing competitiveness by shifting outsourced production volumes to in-house manufacturing, thereby reducing production costs and boosting profitability. 

An official from HLB Pharm stated, "We are maintaining our growth momentum through increased sales across major business divisions. We will continue to build a stable growth foundation by strengthening production competitiveness and improving profitability."